nodes	percent_of_prediction	percent_of_DWPC	metapath
Lorazepam—Ventricular arrhythmia—Aminophylline—chronic obstructive pulmonary disease	0.0119	0.0129	CcSEcCtD
Lorazepam—Hostility—Montelukast—chronic obstructive pulmonary disease	0.0118	0.0129	CcSEcCtD
Lorazepam—Block heart—Formoterol—chronic obstructive pulmonary disease	0.0118	0.0128	CcSEcCtD
Lorazepam—Block heart—Arformoterol—chronic obstructive pulmonary disease	0.0118	0.0128	CcSEcCtD
Lorazepam—Pulmonary function test decreased—Aminophylline—chronic obstructive pulmonary disease	0.0117	0.0127	CcSEcCtD
Lorazepam—Respiratory depression—Aminophylline—chronic obstructive pulmonary disease	0.0117	0.0127	CcSEcCtD
Lorazepam—Gastrointestinal symptom NOS—Salbutamol—chronic obstructive pulmonary disease	0.0107	0.0117	CcSEcCtD
Lorazepam—Paralysis—Formoterol—chronic obstructive pulmonary disease	0.00962	0.0105	CcSEcCtD
Lorazepam—Paralysis—Arformoterol—chronic obstructive pulmonary disease	0.00962	0.0105	CcSEcCtD
Lorazepam—Hyperventilation—Salbutamol—chronic obstructive pulmonary disease	0.00917	0.01	CcSEcCtD
Lorazepam—Memory impairment—Montelukast—chronic obstructive pulmonary disease	0.00834	0.0091	CcSEcCtD
Lorazepam—Injection site pain—Formoterol—chronic obstructive pulmonary disease	0.00819	0.00893	CcSEcCtD
Lorazepam—Injection site pain—Arformoterol—chronic obstructive pulmonary disease	0.00819	0.00893	CcSEcCtD
Lorazepam—Coagulopathy—Salbutamol—chronic obstructive pulmonary disease	0.00811	0.00884	CcSEcCtD
Lorazepam—Coma—Aminophylline—chronic obstructive pulmonary disease	0.00803	0.00875	CcSEcCtD
Lorazepam—Liver injury—Montelukast—chronic obstructive pulmonary disease	0.00778	0.00848	CcSEcCtD
Lorazepam—Aggression—Montelukast—chronic obstructive pulmonary disease	0.00745	0.00813	CcSEcCtD
Lorazepam—Aggression—Salbutamol—chronic obstructive pulmonary disease	0.00719	0.00783	CcSEcCtD
Lorazepam—Disorientation—Aminophylline—chronic obstructive pulmonary disease	0.00713	0.00777	CcSEcCtD
Lorazepam—Leukocytosis—Arformoterol—chronic obstructive pulmonary disease	0.00711	0.00776	CcSEcCtD
Lorazepam—Leukocytosis—Formoterol—chronic obstructive pulmonary disease	0.00711	0.00776	CcSEcCtD
Lorazepam—Thinking abnormal—Salbutamol—chronic obstructive pulmonary disease	0.0069	0.00752	CcSEcCtD
Lorazepam—Atrioventricular block—Formoterol—chronic obstructive pulmonary disease	0.00689	0.00751	CcSEcCtD
Lorazepam—Atrioventricular block—Arformoterol—chronic obstructive pulmonary disease	0.00689	0.00751	CcSEcCtD
Lorazepam—Hepatocellular injury—Montelukast—chronic obstructive pulmonary disease	0.00655	0.00714	CcSEcCtD
Lorazepam—Cystitis noninfective—Arformoterol—chronic obstructive pulmonary disease	0.00653	0.00712	CcSEcCtD
Lorazepam—Cystitis noninfective—Formoterol—chronic obstructive pulmonary disease	0.00653	0.00712	CcSEcCtD
Lorazepam—Cystitis—Arformoterol—chronic obstructive pulmonary disease	0.00646	0.00704	CcSEcCtD
Lorazepam—Cystitis—Formoterol—chronic obstructive pulmonary disease	0.00646	0.00704	CcSEcCtD
Lorazepam—UGT2B15—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00626	0.103	CbGpPWpGaD
Lorazepam—Irritability—Aminophylline—chronic obstructive pulmonary disease	0.00609	0.00664	CcSEcCtD
Lorazepam—Bladder pain—Formoterol—chronic obstructive pulmonary disease	0.00605	0.00659	CcSEcCtD
Lorazepam—Bladder pain—Arformoterol—chronic obstructive pulmonary disease	0.00605	0.00659	CcSEcCtD
Lorazepam—Tension—Roflumilast—chronic obstructive pulmonary disease	0.00565	0.00616	CcSEcCtD
Lorazepam—Pulmonary oedema—Salbutamol—chronic obstructive pulmonary disease	0.00562	0.00613	CcSEcCtD
Lorazepam—Sleep disorder—Formoterol—chronic obstructive pulmonary disease	0.00561	0.00611	CcSEcCtD
Lorazepam—Sleep disorder—Arformoterol—chronic obstructive pulmonary disease	0.00561	0.00611	CcSEcCtD
Lorazepam—Nervousness—Roflumilast—chronic obstructive pulmonary disease	0.00559	0.0061	CcSEcCtD
Lorazepam—Sleep disorder—Montelukast—chronic obstructive pulmonary disease	0.00549	0.00599	CcSEcCtD
Lorazepam—Mental disability—Salbutamol—chronic obstructive pulmonary disease	0.00548	0.00597	CcSEcCtD
Lorazepam—Euphoric mood—Salbutamol—chronic obstructive pulmonary disease	0.00542	0.00591	CcSEcCtD
Lorazepam—Tremor—Roflumilast—chronic obstructive pulmonary disease	0.0054	0.00588	CcSEcCtD
Lorazepam—Disorientation—Montelukast—chronic obstructive pulmonary disease	0.00531	0.00579	CcSEcCtD
Lorazepam—Vertigo—Roflumilast—chronic obstructive pulmonary disease	0.00517	0.00564	CcSEcCtD
Lorazepam—Infection—Roflumilast—chronic obstructive pulmonary disease	0.00467	0.00509	CcSEcCtD
Lorazepam—UGT2B15—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00455	0.0752	CbGpPWpGaD
Lorazepam—Irritability—Montelukast—chronic obstructive pulmonary disease	0.00454	0.00495	CcSEcCtD
Lorazepam—Diclofenac—CXCL8—chronic obstructive pulmonary disease	0.00444	0.201	CrCbGaD
Lorazepam—Irritability—Salbutamol—chronic obstructive pulmonary disease	0.00437	0.00477	CcSEcCtD
Lorazepam—Ataxia—Salbutamol—chronic obstructive pulmonary disease	0.00431	0.0047	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00406	0.00442	CcSEcCtD
Lorazepam—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.00405	0.00442	CcSEcCtD
Lorazepam—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.00402	0.00438	CcSEcCtD
Lorazepam—Visual impairment—Tiotropium—chronic obstructive pulmonary disease	0.00401	0.00437	CcSEcCtD
Lorazepam—Arrhythmia—Aminophylline—chronic obstructive pulmonary disease	0.00394	0.0043	CcSEcCtD
Lorazepam—Alopecia—Aminophylline—chronic obstructive pulmonary disease	0.0039	0.00425	CcSEcCtD
Lorazepam—Feeling abnormal—Roflumilast—chronic obstructive pulmonary disease	0.00387	0.00422	CcSEcCtD
Lorazepam—Tension—Aminophylline—chronic obstructive pulmonary disease	0.00377	0.00411	CcSEcCtD
Lorazepam—Suicidal ideation—Prednisone—chronic obstructive pulmonary disease	0.00375	0.00409	CcSEcCtD
Lorazepam—Nervousness—Aminophylline—chronic obstructive pulmonary disease	0.00373	0.00407	CcSEcCtD
Lorazepam—Arrhythmia—Tiotropium—chronic obstructive pulmonary disease	0.00372	0.00405	CcSEcCtD
Lorazepam—Drowsiness—Montelukast—chronic obstructive pulmonary disease	0.00366	0.00399	CcSEcCtD
Lorazepam—Mania—Prednisone—chronic obstructive pulmonary disease	0.00362	0.00394	CcSEcCtD
Lorazepam—Tremor—Aminophylline—chronic obstructive pulmonary disease	0.0036	0.00392	CcSEcCtD
Lorazepam—Jaundice—Montelukast—chronic obstructive pulmonary disease	0.00357	0.00389	CcSEcCtD
Lorazepam—Drowsiness—Salbutamol—chronic obstructive pulmonary disease	0.00353	0.00385	CcSEcCtD
Lorazepam—Agitation—Aminophylline—chronic obstructive pulmonary disease	0.00353	0.00385	CcSEcCtD
Lorazepam—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.00346	0.00377	CcSEcCtD
Lorazepam—Jaundice—Salbutamol—chronic obstructive pulmonary disease	0.00344	0.00375	CcSEcCtD
Lorazepam—Vision blurred—Tiotropium—chronic obstructive pulmonary disease	0.00341	0.00372	CcSEcCtD
Lorazepam—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.00337	0.00368	CcSEcCtD
Lorazepam—Memory impairment—Prednisone—chronic obstructive pulmonary disease	0.00335	0.00365	CcSEcCtD
Lorazepam—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.00333	0.00363	CcSEcCtD
Lorazepam—Hallucination—Montelukast—chronic obstructive pulmonary disease	0.00327	0.00357	CcSEcCtD
Lorazepam—Visual impairment—Formoterol—chronic obstructive pulmonary disease	0.00324	0.00353	CcSEcCtD
Lorazepam—Visual impairment—Arformoterol—chronic obstructive pulmonary disease	0.00324	0.00353	CcSEcCtD
Lorazepam—Pulmonary oedema—Prednisolone—chronic obstructive pulmonary disease	0.00322	0.00351	CcSEcCtD
Lorazepam—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.00313	0.00341	CcSEcCtD
Lorazepam—Infection—Aminophylline—chronic obstructive pulmonary disease	0.00311	0.00339	CcSEcCtD
Lorazepam—Euphoric mood—Prednisolone—chronic obstructive pulmonary disease	0.00311	0.00339	CcSEcCtD
Lorazepam—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00311	0.00339	CcSEcCtD
Lorazepam—Delirium—Prednisone—chronic obstructive pulmonary disease	0.00306	0.00333	CcSEcCtD
Lorazepam—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.00306	0.00333	CcSEcCtD
Lorazepam—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.00302	0.00329	CcSEcCtD
Lorazepam—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.003	0.00327	CcSEcCtD
Lorazepam—Arrhythmia—Formoterol—chronic obstructive pulmonary disease	0.003	0.00327	CcSEcCtD
Lorazepam—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00299	0.00326	CcSEcCtD
Lorazepam—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00296	0.00323	CcSEcCtD
Lorazepam—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00296	0.00323	CcSEcCtD
Lorazepam—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00294	0.00321	CcSEcCtD
Lorazepam—Infection—Tiotropium—chronic obstructive pulmonary disease	0.00294	0.0032	CcSEcCtD
Lorazepam—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.00293	0.00319	CcSEcCtD
Lorazepam—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.00288	0.00314	CcSEcCtD
Lorazepam—Tension—Formoterol—chronic obstructive pulmonary disease	0.00287	0.00313	CcSEcCtD
Lorazepam—Tension—Arformoterol—chronic obstructive pulmonary disease	0.00287	0.00313	CcSEcCtD
Lorazepam—Chills—Salbutamol—chronic obstructive pulmonary disease	0.00284	0.0031	CcSEcCtD
Lorazepam—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.00284	0.00309	CcSEcCtD
Lorazepam—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.00284	0.00309	CcSEcCtD
Lorazepam—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.00283	0.00309	CcSEcCtD
Lorazepam—Leukocytosis—Prednisone—chronic obstructive pulmonary disease	0.0028	0.00305	CcSEcCtD
Lorazepam—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00279	0.00304	CcSEcCtD
Lorazepam—Visual disturbance—Prednisolone—chronic obstructive pulmonary disease	0.00277	0.00302	CcSEcCtD
Lorazepam—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.00274	0.00299	CcSEcCtD
Lorazepam—Tremor—Formoterol—chronic obstructive pulmonary disease	0.00274	0.00299	CcSEcCtD
Lorazepam—Tension—Salbutamol—chronic obstructive pulmonary disease	0.00271	0.00295	CcSEcCtD
Lorazepam—Agitation—Formoterol—chronic obstructive pulmonary disease	0.00269	0.00293	CcSEcCtD
Lorazepam—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.00269	0.00293	CcSEcCtD
Lorazepam—Tremor—Montelukast—chronic obstructive pulmonary disease	0.00268	0.00292	CcSEcCtD
Lorazepam—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.00268	0.00292	CcSEcCtD
Lorazepam—Agitation—Montelukast—chronic obstructive pulmonary disease	0.00263	0.00287	CcSEcCtD
Lorazepam—Osteoarthritis—Prednisolone—chronic obstructive pulmonary disease	0.00263	0.00287	CcSEcCtD
Lorazepam—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.00259	0.00282	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00255	0.00278	CcSEcCtD
Lorazepam—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.00254	0.00276	CcSEcCtD
Lorazepam—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00253	0.00276	CcSEcCtD
Lorazepam—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.00252	0.00275	CcSEcCtD
Lorazepam—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.00252	0.00275	CcSEcCtD
Lorazepam—Cardiac arrest—Prednisolone—chronic obstructive pulmonary disease	0.0025	0.00272	CcSEcCtD
Lorazepam—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.00248	0.0027	CcSEcCtD
Lorazepam—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.00248	0.0027	CcSEcCtD
Lorazepam—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00243	0.00265	CcSEcCtD
Lorazepam—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00243	0.00265	CcSEcCtD
Lorazepam—UGT2B15—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	0.00239	0.0396	CbGpPWpGaD
Lorazepam—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.00238	0.0026	CcSEcCtD
Lorazepam—Infection—Arformoterol—chronic obstructive pulmonary disease	0.00237	0.00258	CcSEcCtD
Lorazepam—Infection—Formoterol—chronic obstructive pulmonary disease	0.00237	0.00258	CcSEcCtD
Lorazepam—UGT2B15—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	0.00237	0.0391	CbGpPWpGaD
Lorazepam—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	0.00234	0.00255	CcSEcCtD
Lorazepam—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.00233	0.00254	CcSEcCtD
Lorazepam—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.00233	0.00254	CcSEcCtD
Lorazepam—Infection—Montelukast—chronic obstructive pulmonary disease	0.00232	0.00253	CcSEcCtD
Lorazepam—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00231	0.00252	CcSEcCtD
Lorazepam—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.0023	0.00251	CcSEcCtD
Lorazepam—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.00229	0.00249	CcSEcCtD
Lorazepam—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.00226	0.00246	CcSEcCtD
Lorazepam—Infection—Salbutamol—chronic obstructive pulmonary disease	0.00224	0.00244	CcSEcCtD
Lorazepam—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.00223	0.00243	CcSEcCtD
Lorazepam—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.00223	0.00243	CcSEcCtD
Lorazepam—Bromazepam—CYP1A2—chronic obstructive pulmonary disease	0.00222	0.1	CrCbGaD
Lorazepam—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.0022	0.0024	CcSEcCtD
Lorazepam—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.00218	0.00237	CcSEcCtD
Lorazepam—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.00212	0.00231	CcSEcCtD
Lorazepam—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.00212	0.00231	CcSEcCtD
Lorazepam—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.0021	0.00229	CcSEcCtD
Lorazepam—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.00208	0.00226	CcSEcCtD
Lorazepam—Diclofenac—CYP1A1—chronic obstructive pulmonary disease	0.00207	0.0936	CrCbGaD
Lorazepam—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00207	0.00226	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00206	0.00225	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00206	0.00225	CcSEcCtD
Lorazepam—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00206	0.00224	CcSEcCtD
Lorazepam—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00206	0.00224	CcSEcCtD
Lorazepam—Constipation—Formoterol—chronic obstructive pulmonary disease	0.00204	0.00222	CcSEcCtD
Lorazepam—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.00204	0.00222	CcSEcCtD
Lorazepam—Pain—Arformoterol—chronic obstructive pulmonary disease	0.00204	0.00222	CcSEcCtD
Lorazepam—Pain—Formoterol—chronic obstructive pulmonary disease	0.00204	0.00222	CcSEcCtD
Lorazepam—Amnesia—Prednisone—chronic obstructive pulmonary disease	0.00203	0.00222	CcSEcCtD
Lorazepam—GABRB3—Ion channel transport—ATP2C2—chronic obstructive pulmonary disease	0.00202	0.0334	CbGpPWpGaD
Lorazepam—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00202	0.0022	CcSEcCtD
Lorazepam—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.00201	0.0022	CcSEcCtD
Lorazepam—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.002	0.00218	CcSEcCtD
Lorazepam—Diclofenac—CYP1A2—chronic obstructive pulmonary disease	0.002	0.0902	CrCbGaD
Lorazepam—Pain—Montelukast—chronic obstructive pulmonary disease	0.002	0.00218	CcSEcCtD
Lorazepam—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00199	0.00217	CcSEcCtD
Lorazepam—UGT2B15—Phase II conjugation—CYP1A2—chronic obstructive pulmonary disease	0.00199	0.0329	CbGpPWpGaD
Lorazepam—GABRG2—Ion channel transport—ATP2C2—chronic obstructive pulmonary disease	0.00198	0.0328	CbGpPWpGaD
Lorazepam—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00198	0.00215	CcSEcCtD
Lorazepam—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00197	0.00215	CcSEcCtD
Lorazepam—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.00197	0.00214	CcSEcCtD
Lorazepam—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.00197	0.00214	CcSEcCtD
Lorazepam—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00196	0.00214	CcSEcCtD
Lorazepam—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.00195	0.00213	CcSEcCtD
Lorazepam—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.00195	0.00212	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00194	0.00212	CcSEcCtD
Lorazepam—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00194	0.00212	CcSEcCtD
Lorazepam—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.00193	0.0021	CcSEcCtD
Lorazepam—Pain—Salbutamol—chronic obstructive pulmonary disease	0.00193	0.0021	CcSEcCtD
Lorazepam—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.00191	0.00208	CcSEcCtD
Lorazepam—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.00191	0.00208	CcSEcCtD
Lorazepam—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00188	0.00205	CcSEcCtD
Lorazepam—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.00187	0.00203	CcSEcCtD
Lorazepam—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00186	0.00203	CcSEcCtD
Lorazepam—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00186	0.00203	CcSEcCtD
Lorazepam—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00186	0.00203	CcSEcCtD
Lorazepam—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.00186	0.00202	CcSEcCtD
Lorazepam—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00185	0.00202	CcSEcCtD
Lorazepam—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.00185	0.00202	CcSEcCtD
Lorazepam—Irritability—Prednisone—chronic obstructive pulmonary disease	0.00182	0.00199	CcSEcCtD
Lorazepam—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.00182	0.00198	CcSEcCtD
Lorazepam—GABRB3—Ion channel transport—TRPV4—chronic obstructive pulmonary disease	0.0018	0.0297	CbGpPWpGaD
Lorazepam—GABRG2—Ion channel transport—TRPV4—chronic obstructive pulmonary disease	0.00177	0.0292	CbGpPWpGaD
Lorazepam—Amoxapine—SLC6A4—chronic obstructive pulmonary disease	0.00177	0.0797	CrCbGaD
Lorazepam—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00176	0.00192	CcSEcCtD
Lorazepam—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00176	0.00192	CcSEcCtD
Lorazepam—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00176	0.00191	CcSEcCtD
Lorazepam—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.00175	0.00191	CcSEcCtD
Lorazepam—GABRA1—Ion channel transport—ATP2C2—chronic obstructive pulmonary disease	0.00173	0.0286	CbGpPWpGaD
Lorazepam—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.00172	0.00188	CcSEcCtD
Lorazepam—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00171	0.00187	CcSEcCtD
Lorazepam—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00171	0.00187	CcSEcCtD
Lorazepam—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.00168	0.00183	CcSEcCtD
Lorazepam—UGT2B15—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	0.00166	0.0274	CbGpPWpGaD
Lorazepam—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.00166	0.00181	CcSEcCtD
Lorazepam—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.00162	0.00177	CcSEcCtD
Lorazepam—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.00162	0.00176	CcSEcCtD
Lorazepam—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.00158	0.00173	CcSEcCtD
Lorazepam—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00158	0.00172	CcSEcCtD
Lorazepam—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00158	0.00172	CcSEcCtD
Lorazepam—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00155	0.00168	CcSEcCtD
Lorazepam—GABRA1—Ion channel transport—TRPV4—chronic obstructive pulmonary disease	0.00154	0.0255	CbGpPWpGaD
Lorazepam—UGT2B15—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	0.00153	0.0252	CbGpPWpGaD
Lorazepam—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.00152	0.00166	CcSEcCtD
Lorazepam—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00152	0.00165	CcSEcCtD
Lorazepam—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00152	0.00165	CcSEcCtD
Lorazepam—Rash—Formoterol—chronic obstructive pulmonary disease	0.0015	0.00164	CcSEcCtD
Lorazepam—Rash—Arformoterol—chronic obstructive pulmonary disease	0.0015	0.00164	CcSEcCtD
Lorazepam—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.0015	0.00164	CcSEcCtD
Lorazepam—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.0015	0.00164	CcSEcCtD
Lorazepam—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00149	0.00163	CcSEcCtD
Lorazepam—Headache—Formoterol—chronic obstructive pulmonary disease	0.00149	0.00163	CcSEcCtD
Lorazepam—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.00149	0.00163	CcSEcCtD
Lorazepam—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00149	0.00162	CcSEcCtD
Lorazepam—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.00149	0.00162	CcSEcCtD
Lorazepam—Rash—Montelukast—chronic obstructive pulmonary disease	0.00147	0.00161	CcSEcCtD
Lorazepam—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00147	0.0016	CcSEcCtD
Lorazepam—Headache—Montelukast—chronic obstructive pulmonary disease	0.00146	0.0016	CcSEcCtD
Lorazepam—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.00143	0.00156	CcSEcCtD
Lorazepam—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.00142	0.00155	CcSEcCtD
Lorazepam—Rash—Salbutamol—chronic obstructive pulmonary disease	0.00142	0.00155	CcSEcCtD
Lorazepam—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.00142	0.00155	CcSEcCtD
Lorazepam—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00142	0.00154	CcSEcCtD
Lorazepam—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00142	0.00154	CcSEcCtD
Lorazepam—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00141	0.00154	CcSEcCtD
Lorazepam—UGT2B15—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.0014	0.0231	CbGpPWpGaD
Lorazepam—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00139	0.00151	CcSEcCtD
Lorazepam—UGT2B15—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.00138	0.0229	CbGpPWpGaD
Lorazepam—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.00137	0.0015	CcSEcCtD
Lorazepam—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.00137	0.00149	CcSEcCtD
Lorazepam—Amoxapine—HTR2A—chronic obstructive pulmonary disease	0.00136	0.0612	CrCbGaD
Lorazepam—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.00135	0.00147	CcSEcCtD
Lorazepam—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.00134	0.00146	CcSEcCtD
Lorazepam—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.00131	0.00143	CcSEcCtD
Lorazepam—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.00126	0.00137	CcSEcCtD
Lorazepam—Chlorprothixene—HTR2A—chronic obstructive pulmonary disease	0.00121	0.0548	CrCbGaD
Lorazepam—Clonazepam—ALB—chronic obstructive pulmonary disease	0.0012	0.0544	CrCbGaD
Lorazepam—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.00118	0.00129	CcSEcCtD
Lorazepam—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.00117	0.00127	CcSEcCtD
Lorazepam—UGT2B15—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.00116	0.0192	CbGpPWpGaD
Lorazepam—Diclofenac—ALB—chronic obstructive pulmonary disease	0.00115	0.0521	CrCbGaD
Lorazepam—Erythema—Prednisone—chronic obstructive pulmonary disease	0.00115	0.00125	CcSEcCtD
Lorazepam—Pain—Prednisolone—chronic obstructive pulmonary disease	0.0011	0.0012	CcSEcCtD
Lorazepam—Clozapine—CYP1A1—chronic obstructive pulmonary disease	0.00109	0.0493	CrCbGaD
Lorazepam—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.00108	0.00118	CcSEcCtD
Lorazepam—Diazepam—CYP1A2—chronic obstructive pulmonary disease	0.00107	0.0482	CrCbGaD
Lorazepam—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.00106	0.00116	CcSEcCtD
Lorazepam—Agitation—Prednisone—chronic obstructive pulmonary disease	0.00106	0.00115	CcSEcCtD
Lorazepam—Clozapine—CYP1A2—chronic obstructive pulmonary disease	0.00105	0.0476	CrCbGaD
Lorazepam—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.00103	0.00113	CcSEcCtD
Lorazepam—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000997	0.00109	CcSEcCtD
Lorazepam—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000993	0.00108	CcSEcCtD
Lorazepam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—chronic obstructive pulmonary disease	0.000988	0.0163	CbGpPWpGaD
Lorazepam—UGT2B15—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000971	0.016	CbGpPWpGaD
Lorazepam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—chronic obstructive pulmonary disease	0.00097	0.016	CbGpPWpGaD
Lorazepam—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000952	0.00104	CcSEcCtD
Lorazepam—Infection—Prednisone—chronic obstructive pulmonary disease	0.000933	0.00102	CcSEcCtD
Lorazepam—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000916	0.000999	CcSEcCtD
Lorazepam—UGT2B15—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000892	0.0147	CbGpPWpGaD
Lorazepam—Clozapine—HTR2A—chronic obstructive pulmonary disease	0.00089	0.0402	CrCbGaD
Lorazepam—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000854	0.000931	CcSEcCtD
Lorazepam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—chronic obstructive pulmonary disease	0.000848	0.014	CbGpPWpGaD
Lorazepam—UGT2B15—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000846	0.014	CbGpPWpGaD
Lorazepam—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000815	0.000888	CcSEcCtD
Lorazepam—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000814	0.000887	CcSEcCtD
Lorazepam—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000809	0.000882	CcSEcCtD
Lorazepam—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000809	0.000882	CcSEcCtD
Lorazepam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—chronic obstructive pulmonary disease	0.000805	0.0133	CbGpPWpGaD
Lorazepam—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000803	0.000875	CcSEcCtD
Lorazepam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—chronic obstructive pulmonary disease	0.000791	0.0131	CbGpPWpGaD
Lorazepam—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000774	0.000843	CcSEcCtD
Lorazepam—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000767	0.000837	CcSEcCtD
Lorazepam—GABRB3—Transmission across Chemical Synapses—CHRNA5—chronic obstructive pulmonary disease	0.000743	0.0123	CbGpPWpGaD
Lorazepam—GABRG2—Transmission across Chemical Synapses—CHRNA5—chronic obstructive pulmonary disease	0.000729	0.012	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000703	0.0116	CbGpPWpGaD
Lorazepam—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000692	0.000754	CcSEcCtD
Lorazepam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—chronic obstructive pulmonary disease	0.000691	0.0114	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.00069	0.0114	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—APIP—chronic obstructive pulmonary disease	0.00068	0.0112	CbGpPWpGaD
Lorazepam—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000674	0.000734	CcSEcCtD
Lorazepam—GABRA1—Transmission across Chemical Synapses—CHRNA5—chronic obstructive pulmonary disease	0.000637	0.0105	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000626	0.0103	CbGpPWpGaD
Lorazepam—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000621	0.000677	CcSEcCtD
Lorazepam—Diazepam—ALB—chronic obstructive pulmonary disease	0.000617	0.0278	CrCbGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000615	0.0102	CbGpPWpGaD
Lorazepam—GABRB3—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.000605	0.01	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000603	0.00997	CbGpPWpGaD
Lorazepam—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000597	0.000651	CcSEcCtD
Lorazepam—GABRG2—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.000594	0.00982	CbGpPWpGaD
Lorazepam—Rash—Prednisone—chronic obstructive pulmonary disease	0.000592	0.000645	CcSEcCtD
Lorazepam—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000591	0.000645	CcSEcCtD
Lorazepam—Headache—Prednisone—chronic obstructive pulmonary disease	0.000588	0.000641	CcSEcCtD
Lorazepam—GABRB3—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000569	0.0094	CbGpPWpGaD
Lorazepam—GABRG2—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000559	0.00923	CbGpPWpGaD
Lorazepam—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000558	0.000608	CcSEcCtD
Lorazepam—GABRA1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000538	0.00888	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000522	0.00862	CbGpPWpGaD
Lorazepam—GABRA1—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.00052	0.00858	CbGpPWpGaD
Lorazepam—GABRA1—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000488	0.00807	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000471	0.00778	CbGpPWpGaD
Lorazepam—GABRB3—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000464	0.00766	CbGpPWpGaD
Lorazepam—GABRG2—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000455	0.00752	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	0.000451	0.00745	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GC—chronic obstructive pulmonary disease	0.000438	0.00724	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	0.000408	0.00673	CbGpPWpGaD
Lorazepam—GABRA1—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000398	0.00658	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000327	0.00539	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000289	0.00477	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTT1—chronic obstructive pulmonary disease	0.00024	0.00396	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GCLC—chronic obstructive pulmonary disease	0.000237	0.00391	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CTGF—chronic obstructive pulmonary disease	0.000216	0.00357	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000199	0.00329	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	0.000179	0.00295	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	0.000171	0.00283	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTP1—chronic obstructive pulmonary disease	0.000166	0.00274	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—HMOX1—chronic obstructive pulmonary disease	0.000164	0.00271	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—GSTM1—chronic obstructive pulmonary disease	0.000153	0.00252	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	0.000145	0.0024	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000145	0.00239	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000138	0.00228	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000135	0.00224	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	0.000124	0.00205	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000118	0.00196	CbGpPWpGaD
Lorazepam—GABRA1—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	0.0001	0.00166	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—ALB—chronic obstructive pulmonary disease	9.83e-05	0.00162	CbGpPWpGaD
Lorazepam—UGT2B15—Metabolism—NOS3—chronic obstructive pulmonary disease	9.4e-05	0.00155	CbGpPWpGaD
Lorazepam—GABRB3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	8.28e-05	0.00137	CbGpPWpGaD
Lorazepam—GABRG2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	8.13e-05	0.00134	CbGpPWpGaD
Lorazepam—GABRA1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	7.11e-05	0.00117	CbGpPWpGaD
